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Abstract When coexpressed with receptor activity-modifying
protein (RAMP)2 or -3, calcitonin receptor-like receptor
(CRLR) functions as an adrenomedullin (AM) receptor
(CRLR/RAMP2 or -3). Coexpression of rat (r)CRLR with
rRAMP deletion mutants in HEK293T cells revealed that
deletion of residues 93^99 from rRAMP2 or residues 58^64
from rRAMP3 significantly inhibits high-affinity [125I]AM
binding and AM-evoked cAMP production, despite full cell
surface expression of the receptor heterodimer. Apparently, these
two seven-residue segments are key determinants of high-affinity
agonist binding to rAM receptors and of receptor functionality.
Consequently, their deletion yields peptides that are able to serve
as negative regulators of AM receptor function. 6 2002 Fed-
eration of European Biochemical Societies. Published by Else-
vier Science B.V. All rights reserved.
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1. Introduction
In 1998, McLatchie et al. [1] ¢rst described three accessory
proteins, termed receptor activity-modifying proteins
(RAMP1, -2 and -3), which mediate translocation of calcito-
nin receptor-like receptor (CRLR) to the cell surface and de-
termine its ligand speci¢city. Coexpression of RAMP2 or -3
with CRLR leads to both proteins being presented at the
plasma membrane as an adrenomedullin (AM) receptor, while
coexpression with RAMP1 allows CRLR to function as a
calcitonin gene-related peptide (CGRP) receptor [1^4].
Although RAMP2 and -3 share only 30% sequence identity
and di¡er in their tissue distributions, they generate essentially
equivalent AM receptors when coexpressed with CRLR in
mammalian cells [3^5].
Hilairet et al. [5] demonstrated that the speci¢c pharmacol-
ogy conferred by each RAMP is independent of the CRLR
glycosylation state. Instead, they suggest RAMPs determine
ligand speci¢city by directly contributing to the structure of
the ligand-binding pocket or by allosteric modulation of the
conformation of the receptor. Consistent with that idea, we
recently showed that a seven-residue segment in human
(h)RAMP2 (amino acids 86^92) and hRAMP3 (amino acids
59^65) is essential for high-a⁄nity agonist binding to hAM
receptors, but not for the interaction of RAMP with CRLR
[6]. It was also of interest to us that each of these seven-res-
idue segments is located between three conserved residues
(Trp, Cys and Tyr) common to humans, rats and mice [7].
In this study, therefore, we used appropriate deletion mutants
to examine whether the seven-residue segments situated be-
tween the three conserved residues in rat (r)RAMP2 and
rRAMP3 (amino acids 93^99 and 58^64, respectively) are
also necessary for high-a⁄nity agonist binding to rAM recep-
tors.
2. Materials and methods
2.1. Reagents and antibody
[125I]hAM (speci¢c activity, 2 WCi/pmol) was produced in our lab-
oratory [8]. Human KCGRP and AM were purchased from Peptide
Institute (Osaka, Japan). Mouse anti-myc-£uorescein isothiocyanate
(FITC) antibody was from Invitrogen. All other reagents were of
analytical grade and obtained from various commercial suppliers.
2.2. Plasmids
Rat CRLR [9] and RAMP2 and -3 [10] were cloned from the lungs
of Wistar rats by polymerase chain reaction (PCR) using the appro-
priate primers and then modi¢ed to provide a consensus Kozak se-
quence as previously described [11]. Expression vector pCAGGS-
rCRLR was constructed by cloning rCRLR cDNA into the mamma-
lian expression vector pCAGGS/Neo [4] using the 5P XhoI and 3P NotI
sites. In addition, a myc epitope tag (EQKLISEEDL) was ligated, in-
frame, to the 5P end of the two RAMP cDNAs and the native signal
sequences were replaced with MKTILALSTYIFCLVFA [12], after
which the Myc-hRAMPs were cloned into pCAGGS/Neo. Deletion
mutants were created using a Quick Change kit (Stratagene) accord-
ing to the manufacturer’s instructions. The PCR products were all
sequences using an Applied Biosystems 310 Genetic Analyzer.
2.3. Cell culture and DNA transfection
HEK293T cells were maintained in Dulbecco’s modi¢ed Eagle’s
medium supplemented with 10% fetal bovine serum, 100 U/ml pen-
icillin G, 100 Wg/ml streptomycin and 0.25 Wg/ml amphotericin B at
37‡C under a humidi¢ed atmosphere of 95% air/5% CO2. For exper-
imentation, cells were seeded into 24-well culture plates and, upon
reaching 70% con£uence, were transiently transfected with rCRLR
and myc-rRAMPs or their mutant expression constructs using Lipo-
fectamine transfection reagent (Invitrogen) according to the manufac-
turer’s instructions. Brie£y, the cells were incubated for 3 h in 250 Wl
Optimem 1 medium containing 200 ng/well plasmid DNA and 2 Wl/
well Lipofectamine. As a control, some cells were transfected with
empty vector (pCAGGS/Neo). All experiments were performed 48 h
after transfection.
2.4. Fluorescence-activated cell sorting (FACS) analysis
Flow cytometry was performed to assess levels of cell surface ex-
pression of myc-rRAMPs and their deletion mutants coexpressed with
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rCRLR in HEK293T cells. Following transient transfection, the cells
were harvested, washed twice with phosphate-bu¡ered saline (PBS),
resuspended in ice-cold FACS bu¡er [4] and incubated for 60 min at
4‡C in the dark with monoclonal anti-myc-FITC antibody (1:500
dilution). Following two successive washes with FACS bu¡er, the cells
were subjected to £ow cytometry in an EPICS XL £ow cytometer
(Beckman Coulter) and analyzed using EXPO 2 software (Beckman
Coulter).
2.5. Radioligand binding assays
To assess whole-cell radioligand binding, transfected HEK293T
cells in 24-well plates were washed twice with warmed PBS and in-
cubated for 20 min at 37‡C with 0.1% bovine serum albumin (BSA)/
PBS to reduce endogenous AM binding, after which the remaining
adherent cells were washed with ice-cold PBS. The cells were then
incubated for 3 h at 4‡C with 20 pM [125I]hAM in the presence (for
non-speci¢c binding) or absence (for total binding) of the indicated
concentration of unlabeled hAM in modi¢ed Krebs^Ringers^HEPES
medium [4], washed twice with ice-cold PBS, and harvested with 0.5 M
NaOH. In addition, competitive inhibition of [125I]hAM binding was
evaluated by determining total binding in the presence of the indicated
concentrations of unlabeled hAM. The associated cellular radioactiv-
ity was measured in a Q-counter. Speci¢c binding was de¢ned as the
di¡erence between total binding and non-speci¢c binding.
2.6. cAMP measurements
Cells were exposed to hKCGRP or hAM in Hanks’ bu¡er contain-
ing 20 mM HEPES, 0.1% BSA and 0.5 mM 3-isobutyl-1-methylxan-
thine (Sigma) for 15 min at 37‡C, after which the reactions were
terminated by addition of lysis bu¡er (Amersham). The lysates were
then centrifuged at 2000 rpm for 10 min at 4‡C, and the cAMP
contents in samples of the supernatants were assayed using a commer-
cial enzyme immunoassay kit according to the manufacturer’s (Amer-
sham) instructions for a non-acetylation protocol.
2.7. Statistical analysis
Results are expressed as meansTS.E.M. of at least three indepen-
dent experiments. Di¡erences between two groups were evaluated
with Student’s t-tests; di¡erences among multiple groups were eval-
uated with a one-way analysis of variance followed by Sche¡e’s test.
Values of P6 0.05 were considered signi¢cant.
3. Results and discussion
3.1. Cell surface expression of rRAMP deletion mutants
We recently demonstrated that hRAMP2 and hRAMP3
each contain a seven-residue segment (amino acids 86^92
and 59^65, respectively) essential for agonist binding to
hAM receptors, and that these segments are situated between
three residues (Trp, Cys and Tyr) conserved among humans,
rats and mice (Fig. 1) [7]. Therefore, to examine whether the
corresponding seven-residue segments of rRAMP2 and
rRAMP3 confer ligand-binding speci¢city to the rAM recep-
tor, HEK293T cells were transiently cotransfected with
rCRLR and one of two deletion mutants (rRAMP2 D93^99
or rRAMP3 D58^64), after which detailed pharmacological
characterization of the rAM receptor was carried out.
We initially analyzed the cell surface expression of epitope-
tagged mutants using FACS (Fig. 2). Surface immunoreactiv-
ity was detected in only 0.99 T 0.06% of cells expressing the
empty vector, which is well within the 2% limit of resolution
characteristic of FACS analysis. When expressed alone, myc-
rCRLR, -rRAMP2 and -rRAMP3 appeared at the surface of
8.6 T 0.95%, 3.93T 0.05% and 8.47T 0.65% of cells, respec-
tively. With respect to myc-rCRLR and myc-rRAMP2, this
almost certainly re£ects association with corresponding en-
dogenous hRAMP2 and hCRLR, yielding AM receptors
(data not shown). In similar fashion, expressed myc-rRAMP3
is known to associate with endogenous calcitonin receptor to
produce amylin and CGRP receptors [13]. When myc-
rRAMP2 or rRAMP3 was coexpressed with rCRLR, the
frequency of cell surface immunoreactivity increased to
33.6T 0.93% and 27.5 T 0.09%, respectively. In addition, coex-
pression of deletion mutant D93^99 or D58^64 with rCRLR
led to their full expression at the cell surface in 19.1T 0.1%
and 23.9 T 1.78% of cells, respectively.
3.2. Radioligand binding to mutant receptors
We next examined the binding of [125I]AM to receptors
comprised of rCRLR complexed with the indicated mutant
(Fig. 3A). No remarkable di¡erences were detected among
cells expressing empty vector, rCRLR, rRAMP2 or rRAMP3.
In cells coexpressing myc-rRAMP2 or -3 and rCRLR, the
speci¢c AM binding was about 15-fold higher than in control
cells (Mock), an e¡ect that was completely blocked by expres-
sion of the D93^99 or D58^64 mutant.
To determine whether these deletion mutants can act as
dominant negative forms, we assessed the competitive inhibi-
tion of [125I]AM binding to HEK293T cells coexpressing
rCRLR with empty vector, D93^99 or D58^64 (Fig. 3B).
The total AM binding in cells coexpressing D58^64 with
rCRLR was signi¢cantly lower (by 16^20%) than in cells ex-
pressing rCRLR alone and approximated the level of binding
seen under the Mock condition. Thus, D58^64 completely
blocked the activity of endogenous RAMP2 in HEK293T
cells. Coexpression of D93^99 and rCRLR elicited a similar
e¡ect, though total AM binding was only partially inhibited.
3.3. cAMP production mediated via mutant receptors
The functionality of AM receptors made up of rCRLR
complexed with one of the deletion mutants was assessed by
examining AM-evoked cAMP production in HEK293T cells
coexpressing rCRLR and D93^99 or D58^64 (Fig. 4). Both
AM and KCGRP elicited concentration-dependent increases
Fig. 1. Alignment of the amino acid sequences of the N-terminal
domains of human (h), rat (r) and mouse (m) RAMP. Conserved
amino acids are boxed; the asterisk indicates conserved cysteine res-
idues.
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in cAMP in cells expressing rCRLR and myc-rRAMP2 or -3,
though they responded more selectively to AM (EC50 = 1.70
or 0.23 nM, respectively) (Fig. 4A). AM had a small e¡ect on
cells expressing empty vector, with maximal cAMP levels
reaching ca. three-fold over baseline (Fig. 4B), which is indi-
cative of the endogenous expression of hRAMP2. In cells
transfected with rCRLR alone, AM elicited signi¢cant, con-
centration-dependent increases in cAMP (Fig. 4B). And con-
sistent with the above-mentioned binding data (Fig. 3B), AM-
evoked cAMP production was completely blocked by cotrans-
fection of D58^64 and partially inhibited by D93^99 (Fig.
4B).
Our earlier studies showed that seven-residue segments sit-
uated between three residues conserved in both hRAMP2 and
hRAMP3 (amino acids 86^92 and 59^65, respectively) are
crucially involved in the agonist binding to the hAM receptors
[6]. It is notable that these segments show little sequence iden-
tity, and that substituting an alanine for each of the amino
acids in the RAMP2 segment caused no signi¢cant change on
AM-evoked cAMP production. It thus seems unlikely that
any single amino acid residue is responsible for determining
the AM selectivity of the receptor, or that AM binds directly
to these sequences. In the present study, expression of an
rRAMP deletion mutant (D93^99 or D58^64) signi¢cantly
diminished both [125I]AM binding and AM-evoked cAMP
production, despite full cell surface expression of the receptor
heterodimer. Because the seven-residue segment of RAMP2,
unlike that of RAMP3, is not highly conserved between hu-
man and rat (Fig. 1), it seems likely that these sequences
confer selectivity by contributing to the structure of the ligand
binding pocket, or perhaps through allosteric modulation of
the conformation of CRLR, rather than directly binding AM.
In the same study [6], we also observed that two hRAMP2
deletion mutants (D83^85 and D93^96) failed to appear at the
Fig. 2. FACS analysis of HEK293T cells expressing myc-rCRLR,
-rRAMPs and rRAMP deletion mutants. A: Cell surface expression
of the indicated myc-tagged proteins. Forty-eight hours after trans-
fection, cells were incubated for 1 h at 4‡C with monoclonal anti-
myc-FITC antibody; mock incubation with the antibody served as
the control. Cell surface expression of each construct was estimated
by £ow cytometry. Bars represent meansTS.E.M. of three indepen-
dent experiments; *P6 0.002 vs. control. B: Representative results
obtained from cells coexpressing rCRLR with myc-rRAMP2,
-rRAMP3 or rRAMP deletion mutants D93^99 or D58^64. Cell
numbers were estimated by £ow cytometry. Fluorescence intensities
(arbitrary units) from a total of 10 000 cells are shown in each pan-
el; the y-axis indicates the absolute number of immunoreactive cells
at each intensity.
Fig. 3. E¡ects of rRAMP deletion mutants on [125I]AM binding
and agonist-induced cAMP production in HEK293T cells expressing
rCRLR. A: Speci¢c [125I]AM binding. Cells were transiently trans-
fected with the indicated myc-tagged genes and then incubated for
4 h at 4‡C with 20 pM [125I]hAM in the presence or absence of
1 WM unlabeled hAM. Non-speci¢c binding was V298 Bq/Wg pro-
tein. The non-speci¢c/total binding ratio in cells coexpressing
rCRLR and myc-rRAMP2 or -rRAMP3 was V30%. Bars represent
meansTS.E.M. of three experiments; *P6 0.04 vs. Mock. B: Com-
petitive inhibition of [125I]hAM binding to HEK293T cells coex-
pressing rCRLR with empty vector (Mock), D93^99 or D58^64.
All experiments were carried out using 20 pM [125I]hAM. Bars rep-
resent meansTS.E.M. of three experiments; *P6 0.03 vs. Mock;
#P6 0.05 vs. rCRLR-expressing cells.
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cell surface, even when coexpressed with hCRLR. That the
three residues conserved in human, rat and mouse RAMPs
(Trp, Cys and Tyr) were deleted in these mutants is indicative
of those residues’ crucial involvement in the interaction be-
tween CRLR and RAMP, or perhaps in the transport of the
CRLR^RAMP complex to the cell surface.
Finally, we have shown that coexpression of rRAMP2
D93^99 or rRAMP3 D58^64 with rCRLR signi¢cantly inhib-
its speci¢c [125I]AM binding and AM-evoked cAMP produc-
tion in cells coexpressing rCRLR and endogenous hRAMP2.
Like hRAMP2 D86^92 and hRAMP3 D59^65, these mutants
apparently can act as negative regulators of AM receptor
function. Although several studies have addressed the relative
a⁄nities of various RAMP forms for CRLR [2,14^16], addi-
tional studies will be necessary to clarify whether inhibition of
receptor function by dominant negative RAMP mutants is
due to competitive inhibition, formation of heterodimeric
complexes or both.
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Fig. 4. Agonist-evoked cAMP production in HEK293T cells coex-
pressing rCRLR with empty vector, myc-rRAMP2, r-RAMP3,
D93^99 or D58^64. A: Cells were transiently cotransfected with
rCRLR plus myc-rRAMP2 or -rRAMP3, after which they were in-
cubated for 15 min at 37‡C with the indicated concentrations of
hKCGRP or hAM and then lysed. The resultant lysates were ana-
lyzed for cAMP content. Symbols depict meansTS.E.M. of three
experiments. B: Cells transiently coexpressing rCRLR with empty
vector (Mock), D93^99 or D58^64 were exposed to the indicated
concentrations of hAM. Bars represent meansTS.E.M. of three ex-
periments; *P6 0.03 vs. Mock; #P6 0.05 vs. rCRLR-expressing
cells.
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